Speaking of Mol Bio5 Nov 2025

De-risking drug development using functional human tissues

In this episode of Speaking of Mol Bio, Dr. Andre Ghetti, CEO of AnaBios, offers a deep dive into the world of translational preclinical research. AnaBios is redefining early human insights by using ethically sourced, functional human tissues and cells to generate actionable data before compounds ever enter clinical trials. Ghetti walks us through the company’s approach of offering human-relevant safety and efficacy data, validating drug targets, and supporting everything from small startups to major pharma groups.

We learn how AnaBios engages with clients to customize assays, especially in high-need areas like non-opioid pain therapies, fibrosis, and cardiac safety, and how they use a blend of standardized and novel functional assays, some of which required building their own hardware. He also discusses their integration of RT-PCR, RNA-seq, and calcium imaging, including genetically encoded sensors to monitor neuronal activity at scale.

From their use of machine learning to analyze massive data sets, to collaborations with the FDA, to their unique ability to preserve tissue viability across the U.S., AnaBios offers a powerful glimpse into the future of translational biology. Dr. Ghetti also shares advice for young scientists and reflects on what’s next for AnaBios, including oncology and stem-cell model integration.

Subscribe to get future episodes as they drop and if you like what you’re hearing we hope you’ll share a review or recommend the series to a colleague. 

Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology.

For Research Use Only. Not for use in diagnostic procedures.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(54)

The tools, stories, and science behind Absolute Gene-ius

Molecular biology is more than a set of techniques. It is a toolkit for asking better questions. In this special crossover episode of Speaking of Mol Bio, Steve Lewis welcomes Jordan Ruggieri, Senior ...

8 Jul 26min

CRISPR, MPRA, and the genetics of mental health

Some genetic variants may help explain why different psychiatric disorders share overlapping biology. In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Jess McAfee, PhD, and Alejand...

24 Jun 30min

From prototype to production – solving the scale-up gap

Great science doesn’t always translate into a scalable product, and that gap can stall even the most promising innovations. In this Mol Bio Minutes episode, Steve Lewis explores a common challenge in ...

10 Jun 7min

The real cost of PCR - beyond price per reaction

Not all experiments are created equal, and neither are the decisions behind them. In this episode, Cam Cyr explores how scientists navigate the balance between cost and performance in molecular biolog...

27 Mai 30min

The molecular toolkit behind HIV research

HIV research is one of the clearest examples of molecular biology in action. In this Mol Bio Minutes episode, Dr. Ryan Jeep walks through how fundamental molecular techniques power everything from det...

13 Mai 14min

DNA-encoded library use in living cells for drug discovery

In this episode of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Leif Larsen, Director of Biology at Vipergen, about the power of DNA-encoded libraries (DELs) in modern drug discovery. DEL tec...

22 Apr 30min

Choosing the right PCR method for your experiment

In this Mol Bio Minutes mini-episode of Speaking of Mol Bio, Dr. Andrea Hunger walks listeners through the practical differences between three core PCR approaches: endpoint PCR, quantitative PCR (qPCR...

8 Apr 13min

From bench to bushland ─ developing a koala chlamydia vaccine

In this Season 4 premiere of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Nina Pollak from the University of the Sunshine Coast about the development of a single-dose vaccine aimed at protect...

25 Mar 36min